Solara Active Pharma Sciences Limited has announced revisions to its key corporate policies following a Board of Directors meeting held on February 06, 2026. The pharmaceutical company updated two critical governance policies to ensure compliance with recent amendments to SEBI regulations.

Policy Amendments Approved

The board considered and approved amendments to two important corporate policies during their meeting. These revisions demonstrate the company's commitment to maintaining robust governance standards and regulatory compliance.

Materiality Disclosure Policy Update

The company amended its "Policy for Determining Materiality of Events/Information for Disclosure to Stock Exchanges" to align with recent amendments in Regulation 30 of the Securities and Exchange Board of India (Listing Obligations & Disclosure Requirements) Regulations, 2015. This policy governs how the company determines which events and information require disclosure to stock exchanges, ensuring transparency for investors and market participants.

Related Party Transaction Policy Revision

The Board members reviewed and adopted the revised "Policy for Governance of Related Party Transactions" in compliance with amendments to Regulation 23 of SEBI (Listing Obligations and Disclosure Requirement) Regulation, 2015. This policy framework ensures proper governance and transparency in transactions between the company and its related parties.

Policy Accessibility

Both amended policies are now available on the company's website at solara.co.in/investor-relations/policies-and-guidelines/, providing stakeholders with easy access to the updated governance frameworks. The company secretary and compliance officer, Pooja Jaya Kumar, signed the regulatory filing confirming these policy updates.

These policy revisions reflect Solara Active Pharma Sciences' ongoing commitment to maintaining high standards of corporate governance and ensuring full compliance with evolving regulatory requirements in the Indian securities market.

Solara Active Pharma Sciences announced its Q3FY26 financial results, reporting revenue of ₹349 crores alongside a consolidated net loss of ₹17.43 crores. The pharmaceutical company's Board of Directors approved the unaudited financial results for the quarter ended December 31, 2025, during their meeting held on February 6, 2026. The company has engaged strategic advisors to evaluate options for its Ibuprofen business and reassess the previously announced CRAMS & Polymers business demerger.

Financial Performance Overview

The company's Q3FY26 results demonstrate revenue growth compared to the corresponding quarter of the previous year, with total income reaching ₹349 crores against ₹301.80 crores in Q3FY25. However, the company recorded a consolidated net loss of ₹17.43 crores, marking a significant shift from the ₹8.09 crores profit achieved in the same quarter last year.

Strategic Business Transformation and Management Insights

During the earnings conference call held on February 6, 2026, management provided detailed insights into the company's strategic direction. Founder and Non-Executive Director Arun Kumar acknowledged the significant challenges facing the ibuprofen business, noting that Solara was historically the largest ibuprofen manufacturer globally. The company's Growth API business segment delivered strong performance with gross margins exceeding 55% and EBITDA margins of approximately 25%. In contrast, the Base Ibuprofen API business faced persistent headwinds with negative EBITDA margins of -22.90%.

Board Decisions and Strategic Review

The Board of Directors has appointed strategic advisors to evaluate options for the Ibuprofen business, recognizing the structural challenges and pricing pressures in the commodity segment. Management emphasized that the ibuprofen derivatives business remains profitable and is part of the growth segment. The board will also reassess the previously announced scheme for the CRAMS & Polymers business split, with management indicating that an integrated structure may provide more value. A comprehensive roadmap for both initiatives is expected to be presented in the subsequent quarter.

Operational Challenges and Future Plans

The company operates facilities in Pondicherry and Vizag with combined ibuprofen capacity of 10,000-12,000 tons, but current utilization is only around 3,000 tons. The Vizag facility has been mothballed, and management plans to convert it into a multipurpose plant including high potent API capabilities within the next 5-6 months. This transformation will require increased R&D investments and new talent acquisition to support the expanded product portfolio.

Nine-Month Performance Analysis

For the nine months ended December 31, 2025, Solara Active Pharma Sciences reported total income of ₹983.16 crores compared to ₹1,013.12 crores in the corresponding period last year. The company recorded a consolidated net loss of ₹17.01 crores for the nine-month period, contrasting with a profit of ₹2.64 crores in the previous year.

Financial Position and Debt Management

The company continues its rights issue program, having raised ₹311.85 crores out of the total ₹449.95 crores rights issue as of December 31, 2025. Gross debt decreased to ₹630.00 crores from ₹776.00 crores, representing a 19% reduction. CFO Sarat Kumar indicated that ₹113 crores of debt reduction came from rights issue proceeds, while ₹33 crores was generated from operational cash flows. The expected gross debt by May 2026 is projected at approximately ₹499.90 crores.